REVENUE (Tables)

12 Months Ended

Oct. 31, 2022

Revenue from Contract with Customer [Abstract]

The following table presents the company’s total revenue and segment revenue disaggregated by geographical region:


	Life Sciences and Applied Markets		Agilent CrossLab		Diagnostics and Genomics		Total
	(in millions)
Year Ended October 31, 2022:
Americas	$	1,331	$	567	$	784	$	2,682
Europe	907		382		410		1,699
Asia Pacific	1,769		503		195		2,467
Total	$	4,007	$	1,452	$	1,389	$	6,848

Year Ended October 31, 2021:
Americas	$	1,199	$	510	$	695	$	2,404
Europe	893		378		417		1,688
Asia Pacific	1,571		472		184		2,227
Total	$	3,663	$	1,360	$	1,296	$	6,319

Year Ended October 31, 2020:
Americas	$	1,002	$	449	$	517	$	1,968
Europe	746		326		371		1,443
Asia Pacific	1,367		402		159		1,928
Total	$	3,115	$	1,177	$	1,047	$	5,339

The following table presents the company’s total revenue disaggregated by end markets and by revenue type:


		Years Ended October 31,
		2022		2021		2020
	(in millions)
Revenue by End Markets
Pharmaceutical and Biopharmaceutical		$	2,515	2,224		$	1,754
Chemicals and Advanced Materials		1,521		1,328		1,154
Diagnostics and Clinical		963		938		787
Food		617		601		517
Academia and Government		576		576		526
Environmental and Forensics		656		652		601
Total		$	6,848	$	6,319	$	5,339

Revenue by Type
Instrumentation		$	2,907	2,657		$	2,249
Non-instrumentation and other		3,941		3,662		3,090
Total		$	6,848	$	6,319	$	5,339

Contract with Customer, Asset and Liability

The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the years ended October 31, 2021 and 2022:


	Contract Liabilities
	(in millions)

Ending balance as of October 31, 2020	$	446

Net revenue deferred in the period	406
Revenue recognized that was included in the contract liability balance at the beginning of the period	(359)
Change in deferrals from customer cash advances, net of revenue recognized	24

Currency translation and other adjustments	2
Ending balance as of October 31, 2021	$	519
Net revenue deferred in the period	437
Revenue recognized that was included in the contract liability balance at the beginning of the period	(372)
Change in deferrals from customer cash advances, net of revenue recognized	11

Currency translation and other adjustments	(38)
Ending balance as of October 31, 2022	$	557